Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 34, 2023 - Issue 1
Submit an article Journal homepage
856
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review

Qingqing LiGuangdong Women and Children Hospital, Guangzhou, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1700-7084View further author information
ORCID Icon
Article: 2279901 | Received 05 Sep 2023, Accepted 01 Nov 2023, Published online: 09 Nov 2023

References

  • Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373(8):1–5. doi: 10.1056/NEJMoa1502309.
  • Subbiah V, Puzanov I, Blay JY, et al. Pan-cancer efficacy of vemurafenib in BRAF (V600)-mutant non-melanoma cancers. Cancer Discov. 2020;10(5):657–663. doi: 10.1158/2159-8290.CD-19-1265.
  • Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. 2020;135(16):1319–1331. doi: 10.1182/blood.2019000934.
  • Allen CE, Ladisch S, Mcclain KL. How I treat langerhans cell histiocytosis. Blood. 2015;126(1):26–35. doi: 10.1182/blood-2014-12-569301.
  • Kemps PG, Zondag TCE, Arnardóttir HB, et al. Clinicogenomic associations in childhood langerhans cell histiocytosis: an international cohort study. Blood Adv. 2023;7(4):664–679. doi: 10.1182/bloodadvances.2022007947.
  • Awada G, Seremet T, Fostier K, et al. Long-term disease control of langerhans cell histiocytosis using combined BRAF and MEK inhibition. Blood Adv. 2018;2(16):2156–2158. doi: 10.1182/bloodadvances.2018021782.
  • Donadieu J, Larabi IA, Tardieu M, et al. Vemurafenib for refractory multisystem langerhans cell histiocytosis in children: an international observational study. J Clin Oncol. 2019;37(31):2857–2865. doi: 10.1200/JCO.19.00456.
  • Kolenová A, Schwentner R, Jug G, et al. Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH. Blood Adv. 2017;1(6):352–356. doi: 10.1182/bloodadvances.2016003533.
  • Gaspari S, Di Ruscio V, Stocchi F, et al. Case report: early association of vemurafenib to standard chemotherapy in multisystem langerhans cell histiocytosis in a newborn: taking a chance for a better outcome?. Front Oncol. 2021;11:794498. (doi: 10.3389/fonc.2021.794498.
  • Goyal G, Tazi A, Go RS, et al. International expert consensus recommendations for the diagnosis and treatment of langerhans cell histiocytosis in adults. Blood. 2022;139(17):2601–2621. doi: 10.1182/blood.2021014343.
  • Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol. 2018;4(3):384–388. doi: 10.1001/jamaoncol.2017.5029.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.